Bastion Therapeutics’ Post

Surge's €7.5M Funding Round: A Boon for Telemedicine & African Healthcare   The successful €7.5 million fundraising by SurgeCare, a European company pioneering immune system decryption for precision medicine, caught my attention. While Surge itself isn't African, its focus on personalized healthcare solutions resonates deeply with Africa's evolving telemedicine and telehealth space.   Here's why this is exciting news: Precision medicine holds immense potential: Tailoring treatments based on individual needs can significantly improve healthcare outcomes, where access to specialized care is limited. Surge's advancements can inspire VC trends: This significant investment by Eurazeo and other partners could encourage more VC interest in telemedicine solutions across Africa, leading to increased innovation and funding. SurgeLab™M and PreCyte® offer promising applications: These innovations focused on acquiring individualized immune signatures and predicting post-operative complications align perfectly with the need for remote diagnostics and personalized care in telemedicine. A bright future for African health: Surge's success story is a testament to the growing importance of personalized healthcare solutions. I'm optimistic that this will pave the way for more telemedicine advancements in Africa, ultimately improving the health and well-being of the continent's population.   Kudos to the SurgeCare team! Their dedication to precision medicine inspires us all. #telemedicine #africa #healthcare #precisionmedicine #venturecapital

As we anticipate the #LNIF24, let’s remind ourselves the true spirit of the forum by drawing inspiration from the remarkable journey of David Fajgenbaum, MD, MBA, MSc., co-founder of Every Cure, who personifies the essence of #collaboration in #healthcare.   David's story is rooted in repurposing a drug to cure a #raredisease, a narrative that now forms the core of Every Cure, which has repurposed 17 FDA-approved drugs to date.   Together with Tania Simoncelli, Vice President of Science in Society at the Chan Zuckerberg Initiative (CZI), and others, they were able to build collaborative research networks for rare disease communities and more.   The Lake Nona Impact Forum, serving as a dynamic hub for innovations and collaborations, has been instrumental in propelling David's healthcare mission forward. According to Gloria Caulfield, VP of Strategic Alliances at Tavistock Development Company and President of Lake Nona Institute, David's work epitomizes the true spirit of the Impact Forum.   #AdversityToImpact https://lnkd.in/eNnwiz9

Check out my recent pitch at the MedInvest conference in San Francisco. We are making great progress. We have filled about half of our Series B. We would like to welcome additional investors. #Newronika #Brainmodulation #Parkinsons #Neuromodulation #DBS #adaptiveDBS #aDBS #venturecapital #alphaDBS

I'm thrilled to announce that I have joined the Journeys Metabolic team! I've said for many years that I am on a mission to "change the weight of the world." As part of this mission, I founded Heartland Weight Loss; the first insurance-based Obesity Medicine clinic in the Greater Kansas City area. Over the past five years, we have seen phenomenal growth, primarily driven by referrals from amazing clinicians in the area. In 2022, I opened a second location in Lawrence, Kansas (hiring Maribeth Orr, D.O., DABFM, DABOM to anchor that space). Again - success. The world clearly needs (and wants) brick-and-mortar Obesity Medicine clinics! However, scaling an in-person model bigger and bigger simply isn't my cup of tea - nor is it an effective way to bring evidence-based therapies to the masses. With the recent explosion of interest in this field, I have had multiple offers to partner with technology companies. I've never been opposed to the idea - it's a great way to effectively disseminate ten years of knowledge/experience to a bigger audience. Sadly, most of these tech startups are on a mission to either capitalize upon prescribing GLP-1 agonists to as many people as possible and/or promote the outdated, unscientific narrative of "eat-less, move-more" combined with some sort of motivational tool to help people embrace the misery that narrative creates. When I was approached by Journeys Metabolic and dug into their product, it was immediately clear that the leadership of this company gets it. The entire mission of the program is to help patients with metabolic health by focusing on repairing the underlying pathology that happens upstream (at the cellular level), which will inevitably have an impact downstream - improving all sorts of cardiometabolic diseases - including obesity. With a mission grounded in people and results (NOT prescriptions and profits) and a leadership team passionate about metabolic health, I couldn't NOT be a part of this company! I believe Journeys has what it takes to turn this epidemic of chronic disease around - at scale. I'm excited to see what happens as we explode into the marketplace in 2024!

Can't wait to dive deep into all things #regenerativeag, #climate, #impactinvesting over the next couple of days with friends old and new at the Regenerative Food Systems Investment Forum. This should be a very interesting experience relative to #climateweeknyc a couple weeks ago, and I'm excited to see what carries over and what is distinct. I know we'll be closer to action on the ground here, which I find particularly inspiring on a personal level, but the sheer scale of efforts evident at Climate Week is inspiring in it's own way as well. Related: I am truly honored to be named on the "40 Under 40" list by the St. Louis Business Journal, but I have to admit that being in the "just barely still under 40" camp, I'm more focused than ever on how we turn all the talent, technology, energy, and investment in our space into real impact at scale. At HabiTerre, we are tirelessly working to bridge the gap between rigor and scale to develop environmental markets in agriculture. True, meaningful impact requires both scientific integrity in how we measure/incentivize outcomes and the ability to bring that to scaled application. One thing I know for certain: uncertainty does not justify inaction. We'll all have to be a little brave in the process knowing that there is no such thing as a perfectly right climate solution, but there is a perfectly wrong one: doing nothing while waiting for a perfect solution.

Humbled that Healx was awarded the 'LIFE SCIENCE AI AWARD' at the #BusinessWeeklyAwards yesterday. With over 5,000 startups in the Cambridge Cluster (UK), Europe's leading Tech and Biotech Cluster, this is an incredible recognition. Beyond the award itself, this is a significant milestone that highlights how AI is becoming a game-changer in drug discovery, especially in the rare disease space. At Healx, we’re not just using AI for the sake of technology, but to accelerate the development of treatments that can change lives—treatments that might not have been discovered using traditional methods. This award is a reminder of the potential AI holds to reshape human health and bring hope to communities that have long been underserved. The future of medicine is here, and it’s exciting to be part of a movement that is bridging the gap between the much needed innovation to achieve patient impact at scale. Huge thank you to our team, partners, and everyone who believes in our rare disease mission. This is just the beginning... #AI #RareDiseases #HealthcareInnovation #DrugDiscovery #Tech4Good #Biotech

📣 Dive Deeper into STING & TLR Innovations! 🚀 Missed our recent webinar, "Harnessing STING & TLR: Current Developments, Clinical Trials, and Key Players in the Landscape"? Don't worry, you can still catch up! Watch the session on demand to explore the latest advancements in the STING & TLR pipeline, discover new combination therapies, and dive into innovative strategies shaping the future of treatment. 🔗 Watch Now: https://ter.li/z3x8at Stay informed and ahead in the dynamic field of STING & TLR-targeted therapies! #ImmunoOncology #STING #TLR #Checkpoint

Sarah Clifford and Beverly Romero have thoroughly enjoyed attending the inaugural CPATH Global Impact conference. 🌎 Some highlights: * 💡 Insightful discussion on the opportunities for private-public partnerships in drug development, especially rare disease.  * 🤝 The value of bringing all voices together- patients, regulators and industry.  * 🗨 Hearing powerful, personal stories from patients and caregivers that remind us why we do what we do.  * 🔍 Patient perspectives on how we talk about their conditions and experiences - rethinking "living experience" vs "lived"  * 💫 The importance of not working in silos, sharing knowledge and finding ways to "connect the dots" - one of the conference themes #CPath #GlobalImpact #DrugDevelopment #RareDisease #PatientCentricity

There's still time to sign up for this event, co-hosted by @AHNSEndo & @ThyCaInc where we'll discuss recurrences. Join us: https://lnkd.in/g9Z-iqCh #ThyroidCancer #ThyCa #ThyroidCancerSurvivor #ThyCaSurvivor #ThyroidCancerWarrior #ThyCaWarrior

#ICYMI: ASCO 2024 in Review! As we look back at ASCO 2024, we're reminded of the powerful connections and the insightful discussions we had. We've put together a video to share these special moments with you. From our team's insights to the engaging interactions at our booth, relive the event with us! 👉 Click below to watch the video. #ASCO2024 #HealthcareInnovation #OncologyResearch #Caidya